After a @ - to @-day run-in phase with a ticagrelor @-mg loading dose ( LD ) followed by a ticagrelor @-mg twice-daily maintenance dose ( MD ) , aspirin-treated patients ( N = @ ) with stable coronary artery disease were randomized to continue ticagrelor or switch to prasugrel @-mg once-daily MD , with or without a @-mg LD .